JP2019528082A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528082A5
JP2019528082A5 JP2019517135A JP2019517135A JP2019528082A5 JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5 JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5
Authority
JP
Japan
Prior art keywords
domain
antibody
fusion protein
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019517135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/087620 external-priority patent/WO2017211321A1/zh
Publication of JP2019528082A publication Critical patent/JP2019528082A/ja
Publication of JP2019528082A5 publication Critical patent/JP2019528082A5/ja
Priority to JP2021088589A priority Critical patent/JP2021143186A/ja
Priority to JP2024087108A priority patent/JP7809372B2/ja
Pending legal-status Critical Current

Links

JP2019517135A 2016-06-08 2017-06-08 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 Pending JP2019528082A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021088589A JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A JP7809372B2 (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610404956 2016-06-08
CN201610404956.7 2016-06-08
PCT/CN2017/087620 WO2017211321A1 (zh) 2016-06-08 2017-06-08 增强激动型抗体活性的抗体重链恒定区序列

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021088589A Division JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Publications (2)

Publication Number Publication Date
JP2019528082A JP2019528082A (ja) 2019-10-10
JP2019528082A5 true JP2019528082A5 (enExample) 2019-11-21

Family

ID=60578403

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019517135A Pending JP2019528082A (ja) 2016-06-08 2017-06-08 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2021088589A Pending JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A Active JP7809372B2 (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021088589A Pending JP2021143186A (ja) 2016-06-08 2021-05-26 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
JP2024087108A Active JP7809372B2 (ja) 2016-06-08 2024-05-29 アゴニスト抗体の活性を増強する抗体重鎖定常領域配列

Country Status (5)

Country Link
US (1) US12145993B2 (enExample)
EP (1) EP3470424B1 (enExample)
JP (3) JP2019528082A (enExample)
CN (2) CN107474136B (enExample)
WO (1) WO2017211321A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3317297A4 (en) 2015-06-30 2019-03-20 Sanford-Burnham Medical Research Institute BTLA FUSION PROTEIN AGONISTS AND USES THEREOF
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
PE20201339A1 (es) * 2017-12-19 2020-11-25 Univ Rockefeller Variantes de dominio de fc de igg humana con funcion efectora mejorada
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
JP7284759B2 (ja) * 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
JP2022513653A (ja) * 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
CN113728008B (zh) * 2019-04-10 2024-04-09 南开大学 抗cd40抗体及其用途
CN110981958B (zh) * 2019-08-23 2020-10-20 四川大学华西医院 一种pd-l1抗体
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
EP4069291A1 (en) 2019-12-03 2022-10-12 Evotec International GmbH Interferon-associated antigen binding proteins and uses thereof
CN110862455B (zh) * 2019-12-03 2021-12-21 源道隆（苏州）医学科技有限公司 可结合cd47的多肽及其应用
EP4071167A4 (en) * 2019-12-03 2024-03-06 Shanghai Jiao Tong University School of Medicine ANTIBODIES FC REGION WITH INCREASED FCGRIB AFFINITY
MA59827B1 (fr) 2020-05-26 2024-10-31 Boehringer Ingelheim International Gmbh Anticorps anti-pd-1
CN114591428B (zh) * 2020-12-04 2024-05-28 上海交通大学医学院 抗Dsg1抗体及其应用
KR102671409B1 (ko) * 2021-03-02 2024-05-31 진화섭 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
CN118339300A (zh) * 2024-01-02 2024-07-12 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
CN1993378A (zh) * 2004-08-03 2007-07-04 转化技术制药公司 Rage融合蛋白及使用方法
US20070128193A1 (en) * 2004-12-22 2007-06-07 O'neil Karyn T GLP-1 agonists, compositions, methods and uses
JP2009514508A (ja) * 2005-10-24 2009-04-09 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
EP2993188B1 (en) * 2009-04-20 2020-08-19 Kyowa Kirin Co., Ltd. Anti cd40 antibody containing igg2 having three amino acid mutations introduced therein
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
CA2827923C (en) * 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
US9890378B2 (en) * 2012-05-11 2018-02-13 Merck Sharp & Dohme Corp. Surface anchored light chain bait antibody display system
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
MD20180107A2 (ro) * 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
EP3068798B1 (en) 2013-11-12 2020-10-07 OGD2 Pharma Human igg1 derived antibody with pro-apoptotic activity
AU2015210750B2 (en) * 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
EP3131926A1 (en) * 2014-04-16 2017-02-22 UCB Biopharma SPRL Multimeric fc proteins
DK3148579T3 (da) * 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
CN106535932A (zh) * 2014-06-05 2017-03-22 阿肯色大学评议会 抗体引导的疫苗和用于产生快速成熟的免疫应答的方法
PL3221346T3 (pl) * 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
TWI711630B (zh) * 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
CA3005855A1 (en) * 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017211321A1 (zh) * 2016-06-08 2017-12-14 上海交通大学医学院 增强激动型抗体活性的抗体重链恒定区序列
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
EP4071167A4 (en) * 2019-12-03 2024-03-06 Shanghai Jiao Tong University School of Medicine ANTIBODIES FC REGION WITH INCREASED FCGRIB AFFINITY
WO2021222894A1 (en) * 2020-05-01 2021-11-04 Bolt Biotherapeutics, Inc. Anti-dectin-2 antibodies
CN114106174A (zh) * 2020-08-27 2022-03-01 苏州景涞医疗科技有限公司 低毒性抗ox40抗体、其药物组合物及应用

Similar Documents

Publication Publication Date Title
JP7809372B2 (ja) アゴニスト抗体の活性を増強する抗体重鎖定常領域配列
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
US12029761B2 (en) Guidance and Navigation Control proteins and method of making and using thereof
JP2020530289A5 (enExample)
JP2020521452A (ja) 標的化免疫寛容
CA3174097A1 (en) T-cell modulatory polypeptides with conjugation sites and methods of use thereof
JP2017524367A5 (enExample)
JP2018512430A5 (enExample)
JP2023541771A (ja) リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
JP2017533207A5 (enExample)
CN121779568A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
JP2023550419A5 (enExample)
CA3058262A1 (en) Chimeric polypeptides and methods of altering the membrane localization of the same
JP2023515196A (ja) 脂肪酸分子とコンジュゲートされた抗体及びその使用
CN115515981A (zh) 抗肿瘤相关抗原抗体及其用途
WO2023147331A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
Fine et al. Mechanism-driven design of multispecific antibodies for targeted disease treatment
AU2023234457A1 (en) Anti-mesothelin antibodies and uses thereof
AU2023218343A1 (en) Anti-il13ra2 antibodies and uses thereof
KR20250102074A (ko) 항-5t4 항체 및 이의 용도
CN120187757A (zh) 抗EGFRvIII抗体及其用途
WO2024182475A2 (en) Anti-ror2 antibodies and uses thereof
WO2024076864A2 (en) Anti-ror1 antibodies and uses thereof
WO2025147472A1 (en) Anti-611-ctf p95her2 antibodies and uses thereof